Evidence map›Paper›PMID 39999366›Full record

ArticleJournal of clinical hypertension (Greenwich, Conn.)2025

Diabetes Mellitus and Hyperlipidemia Status Among Hypertensive Patients in the Community and Influencing Factors Analysis of Blood Pressure Control.

Shijia Zhang, Yunou Yang, Xiongfei Chen, Liumei Fan, Jiagang Wu, Xiangyi Liu, Weiquan Lin, Zhiyu Zhai, Guozhen Lin, Hui Liu and 1 more

Abstract read
In one paragraph

Article in Journal of clinical hypertension (Greenwich, Conn.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shijia ZhangDepartment of Chronic Diseases Control and Prevention, Guangzhou Center for Disease Control and Prevention, Guangzhou, China.ORCID 0009-0009-0372-9669
Yunou YangDepartment of Chronic Diseases Control and Prevention, Guangzhou Center for Disease Control and Prevention, Guangzhou, China.
Xiongfei ChenDepartment of Chronic Diseases Control and Prevention, Guangzhou Center for Disease Control and Prevention, Guangzhou, China.
Liumei FanDepartment of Chronic Diseases Control and Prevention, Guangzhou Baiyun District Center for Disease Control and Prevention, Guangzhou, China.
Jiagang WuDepartment of Chronic Diseases Control and Prevention, Guangzhou Center for Disease Control and Prevention, Guangzhou, China.
Xiangyi LiuDepartment of Chronic Diseases Control and Prevention, Guangzhou Center for Disease Control and Prevention, Guangzhou, China.
Weiquan LinDepartment of Chronic Diseases Control and Prevention, Guangzhou Center for Disease Control and Prevention, Guangzhou, China.
Zhiyu ZhaiDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, China.
Guozhen LinDepartment of Chronic Diseases Control and Prevention, Guangzhou Center for Disease Control and Prevention, Guangzhou, China.
Hui LiuDepartment of Chronic Diseases Control and Prevention, Guangzhou Center for Disease Control and Prevention, Guangzhou, China.
Qin ZhouDepartment of Chronic Diseases Control and Prevention, Guangzhou Center for Disease Control and Prevention, Guangzhou, China.

Funding

Guangzhou Science and Technology Plan Project 2023A03J0458The Key Project of Medicine Discipline of Guangzhou 2025-2027-12The Two New Projects of Health Science and Technology in Guangzhou 20241A040005
6 · The paper itself

Abstract

To evaluate the prevalence of type 2 diabetes mellitus (T2DM) and hyperlipidemia in hypertensive patients in South China and assess the relationship between these comorbidities and blood pressure control to develop targeted strategies for hypertension management. Data from the 2020 Guangzhou National Basic Public Health Service Program were analyzed using Chi-square tests, t-tests, and logistic regression with R 4.1.2. Among 275,789 hypertensive patients, the blood pressure control rate was 51.51%. The prevalence of T2DM and hyperlipidemia comorbidities was 12.79%, with 12.78% for T2DM alone, 33.54% for hyperlipidemia alone, and 40.89% with no comorbidities. Blood pressure control rates significantly differed by comorbidity (p < 0.05): 52.84% for those without T2DM/hyperlipidemia, 54.18%, 49.25% for T2DM or hyperlipidemia alone, and 50.52% for both conditions. Multivariate analysis indicated a lower blood pressure control rate in patients with hyperlipidemia alone (OR = 1.144) or both T2DM and hyperlipidemia (OR = 1.082), and a higher rate in those with T2DM alone (OR = 0.936). Subgroup analysis revealed that males, older age, higher education, obesity, alcohol use, lack of physical activity, and poor medication adherence were associated with lower control rates. This study found a high prevalence of diabetes and hyperlipidemia among hypertensive patients in Guangzhou. Additionally, hypertensive patients with hyperlipidemia had poorer blood pressure control compared to other diabetic patients. Key factors such as obesity, being overweight, and unhealthy lifestyle choices significantly impact blood pressure management in this population. Therefore, comprehensive measures should be implemented to integrate lipid management into community health efforts and to effectively control blood pressure levels among hypertensive patients.

Indexed as

Diabetes Mellitus, Type 2HyperlipidemiasHypertensionAdultAgedAntihypertensive AgentsBlood PressureBlood Pressure DeterminationChinaComorbidityCross-Sectional StudiesFemaleHumansMaleMiddle AgedPrevalenceAntihypertensive Agentsblood pressure controldiabeteshyperlipidemiahypertension

Identifiers

PMID39999366
PMCPMC11856054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.